VACCINE INDUSTRY CONSULTATION ON COVID19

SUPPLY AND PROCUREMENT UPDATE
Expedite access to Covid-19 vaccines by building on push and pull contracts

To secure at least 2Bds by end 2021, of which 950Mds for AMC countries

Achieve the lowest price on the market drawing on the financing and de-risking provided by the push and pull contracts and the pooled volumes

Balanced geographically diverse portfolio across multiple vaccine platforms

Purpose of the 2020 Tender was to achieve 4 key objectives to provide equitable vaccine access

KEY OBJECTIVES

- Speed
- Volumes
- Price
- Balanced Portfolio

COVAX to establish pull contracts - UNICEF and PAHO to establish procurement and supply agreements
1.6Bds on purchase orders
1.5Bds shipped to 145 Participants
- +650Mds delivered based on Advance Purchase Agreements to 142 participants
- +850Mds delivered based on donations to 107 participants
- 1.4Bds delivered to 87 participants funded under Advance Market Commitment
950Mds delivered to AMC countries in January
2Bds available for supply in April
A balanced portfolio has been achieved, with 11 products now having achieved WHO EUL.

**Key Objectives**

- **Volume**
- **Balanced Portfolio**
- **Price**
- **Speed**

**A balanced portfolio has been achieved, with 11 products now having achieved WHO EUL**

- **475** Discovery through regulatory review
- **36** Approved*
- **11** WHO EUL

**COVAX PORTFOLIO**
- **SANOFI/GSK, NOVAVAX, SERUM LS, CLOVER**
- **CLOVER, NOVAVAX, SERUM LS**
- **PFIZER, MODERNA**
- **PFIZER, MODERNA**
- **ASTRAZENECA, SERUM LS, JANSSEN**
- **ASTRAZENECA, SERUM LS, JANSSEN GAMALEYA (cond.)**
- **-**
- **-**
- **-**
- **-**

**UNICEF LTA**
- **-**
- **-**
- **-**
- **-**
- **-**
- **-**
- **-**

**Source:** UNICEF COVID-19 Vaccine Market Dashboard, May 2022

**Doses delivered by vaccine platform**

- Recombinant Viral Vector
- mRNA
- Inactivated

**Doses delivered by supplier**

- AstraZeneca
- Beijing Institute of Biological Products
- Janssen
- Moderna
- Pfizer
- Serum Institute

* Emergency / conditional use, licensure, special access and WHO EUL.
Several manufacturers have offered supplies at ‘not for profit’ prices during the acute pandemic phase, including as part of their push funding agreements. While initially manufacturers were unwilling to allow publication of prices, most suppliers have now agreed for UNICEF to publish COVID19 prices.

ACHIEVED: For a decade, UNICEF has been committed to **pricing transparency**

- As a core principle in itself
- To support governments and partners in making informed decisions on vaccine introductions
- To help foster a competitive, diverse supplier base for global public goods
Aimed to accelerate access by building on push & pull contracts, supply ramped up greatly by Q4

- First doses delivered by COVAX **within one month of the first mass vaccination campaign** anywhere in the world
- **Responsiveness from donors** to COVAX’s request in Q2 2021 for dose donations, starting large scale in July
- **Supply finally ramping up in Q4** based on multiple supply channels
Having reflected on the progress achieved to date against the objectives of the tender, UNICEF and partners are now looking to the future to continue making progress towards vaccine equity.

We will hear more on this today, including perspectives from UNICEF and our partners on topics such as:

- The general supply landscape and demand signals
- How countries are being supported in their COVID-19 vaccination efforts
- Key regulatory updates impacting countries and suppliers
- How to prepare for the future and look towards a gradual normalization of processes